Erste randomisierte klinische Studie zur Bewertung des besten chirurgischen Ansatzes für die partielle Nephrektomie mit einem Single-Port-Robotersystem bei der Behandlung des lokalisierten Nierenzellkarzinoms (K3)
Standard Flank Approach vs Supine Approach für robotergestützte partielle Nephrektomie: eine randomisierte klinische Studie
This study aims to find out which surgical position is safer and works better for patients candidate to robot-assisted partial nephrectomy (RAPN) - a minimally invasive procedure to remove a small kidney tumor while preserving healthy kidney tissue.
During this operation, the patient can be placed in two different positions:
- the standard flank position, where the patient lies on their side
- a newer supine position, where the patient lies on their back using a technique called Supine Anterior Retroperitoneal Approach (SARA).
Both approaches are performed using the Da Vinci® Single Port (SP) robotic system, a state-of-the-art surgical robot that allows the operation to be done through a single small incision.
The traditional flank position has been used for many years, but it can be uncomfortable for patients and may increase the risk of certain anesthetic or nerve-related complications, especially in people with higher body weight. The new supine SARA technique could make surgery faster, safer, and less painful, but it has not yet been tested in a randomized study.
This is the first clinical trial designed to directly compare these two approaches in patients with small and localized kidney cancers (tumors ≤7 cm, stage cT1).
The study will include 124 patients treated at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy - a leading center in robotic urologic surgery.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Study Objectives
Primary Objective:
To compare the outcomes of RAPN performed with the SARA approach versus the standard flank approach in achieving a "trifecta outcome," defined as:
- No intraoperative adverse events;
- Negative (cancer-free) surgical margins;
- Hospital discharge on postoperative day 1.
Secondary Objectives:
- To compare both approaches according to the rate of achievement of two out of three outcomes, and according to each outcome composing the trifecta separately.
- To evaluate postoperative recovery, including pain scores, time to first walk, time to first flatus, total use of pain medication, and readiness for discharge.
- To compare the rates and severity of postoperative complications within 30 days after surgery.
- To assess surgical parameters such as total operative time, ischemia time, and blood loss.
- To analyze functional outcomes, such as kidney function recovery (Δ eGFR at 30 days).
Study Design This is a prospective, single-center, randomized controlled trial conducted at the Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Eligible participants will be randomly assigned 1:1 to one of two groups:
Group A (Control): Standard flank approach (transperitoneal or retroperitoneal) using the Da Vinci SP system. Patients are positioned laterally (on their side) with the operative flank elevated at a 12-15° angle. The Da Vinci SP robotic system is docked either transperitoneally or retroperitoneally through a single access port. The tumor is resected and kidney reconstruction is performed according to standard RAPN procedures Group B (Experimental): Supine anterior retroperitoneal approach (SARA) using the Da Vinci SP system. Patients are positioned supine with a mild Trendelenburg tilt (0°-10°). A retroperitoneal space is created through an anterior incision, providing direct access to the kidney without repositioning. The same Da Vinci SP system and standard nephron-sparing techniques are used.
Both groups follow identical perioperative protocols for anesthesia, analgesia, and postoperative care.
Population Adults (age 18 or older) with a single kidney tumor measuring up to 7 cm, who are eligible for robotic partial nephrectomy with the Da Vinci SP system, may be invited to participate. Patients with kidney tumor more than 7 cm or advanced tumors infiltrating the surroinding tissues, solitary kidneys, previous kidney surgery on the same kidney, or severe kidney disease will not be eligible.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Paolo Dell'Oglio, MD PhD
- Telefonnummer: +393407981232
- E-Mail: paolo.delloglio@ospedaleniguarda.it
Studieren Sie die Kontaktsicherung
- Name: Stefano Tappero, MD
- Telefonnummer: +393287132369
- E-Mail: stefano.tappero@ospedaleniguarda.it
Studienorte
-
-
-
Milan, Italien, 20162
- Rekrutierung
- ASST Grande Ospedale Metropolitano Niguarda
-
Kontakt:
- Paolo Dell'Oglio, MD PhD
- Telefonnummer: +393407981232
- E-Mail: paolo.delloglio@ospedaleniguarda.it
-
Kontakt:
- Stefano Tappero, MD
- Telefonnummer: +390264447896 +393287132369
- E-Mail: stefano.tappero@ospedaleniguarda.it
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
- Age ≥ 18 years;
- Presence of a single, unilateral, primary renal mass ≤ 7 cm in diameter (clinical stage cT1) documented CT scan
- No evidence of systemic disease or lymph node involvement;
- Candidate for robot-assisted partial nephrectomy using the Da Vinci SP platform;
- Signed informed consent
- Absence of solitary kidney status
- No previous partial nephrectomy/ies on the same kidney
- Absence of preoperative chronic kidney disease (CKD) stage 5
- Absence of any condition that makes mandatory or significantly more adequate the choice of a specific approach over the others (e.g., multiple previous major abdominal surgeries, horseshoe kidney, presence of stomas)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Sonstiges: GROUP A - STANDARD FLANK APPROACH
Patients are positioned laterally (on their side) with the operative flank elevated at a 12-15° angle. The Da Vinci SP robotic system is docked either transperitoneally or retroperitoneally through a single access port. |
Patients are positioned laterally (on their side) with the operative flank elevated at a 12-15° angle. The Da Vinci SP robotic system is docked either transperitoneally or retroperitoneally through a single access port. |
|
Experimental: GROUP B - Supine anterior retroperitoneal approach (SARA).
Patients are positioned supine with a mild Trendelenburg tilt (0°-10°). A retroperitoneal space is created through an anterior incision, providing direct access to the kidney without repositioning. |
Patients are positioned supine with a mild Trendelenburg tilt (0°-10°). A retroperitoneal space is created through an anterior incision, providing direct access to the kidney without repositioning |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
TRIFECTA
Zeitfenster: Intra and perioperative
|
Trifecta is defined as the coexistence of these three conditions:
|
Intra and perioperative
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Partial trifecta achievement
Zeitfenster: Intra and perioperative
|
Secondary end point of the study is to compare RAPN performed with the SARA approach vs RAPN performed with standard flank approach according to the rate of achievement of two out of three outcomes, and lastly according to each outcome composing the trifecta separately. |
Intra and perioperative
|
|
30 day complications
Zeitfenster: 30 postoperative days
|
complications |
30 postoperative days
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Paolo Dell'Oglio, MD PhD, ASST Grande Ospedale Metropolitano Niguarda
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Urologische Neubildungen
- Verhalten
- Soziales Verhalten
- Nierentumoren
- Täuschung
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 5448_16.04.2025_N_bis
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .